Wing Yan Mak1,2, Anthony Buisson1,3,4, Michael J Andersen1, Donald Lei1, Joel Pekow1, Russell D Cohen1, Stacy A Kahn1, Bruno Pereira5, David T Rubin6. 1. Inflammatory Bowel Disease Center, University of Chicago Medicine, 5841 S. Maryland Ave. | MC4076|, Chicago, IL, 60637, USA. 2. Department of Medicine, Queen Elizabeth Hospital, Yau Ma Tei, Hong Kong. 3. Inserm, CHU Clermont-Ferrand, 3iHP, Service d'Hépato-Gastro Entérologie, Université Clermont Auvergne, Clermont-Ferrand, France. 4. 3iHP, Inserm U1071, M2iSH, USC-INRA 2018, Université Clermont Auvergne, 63000, Clermont-Ferrand, France. 5. CHU Clermont-Ferrand, DRCI, Unité de Biostatistiques, Université Clermont Auvergne, Clermont-Ferrand, France. 6. Inflammatory Bowel Disease Center, University of Chicago Medicine, 5841 S. Maryland Ave. | MC4076|, Chicago, IL, 60637, USA. drubin@medicine.bsd.uchicago.edu.
Abstract
BACKGROUND: Persistent active endoscopic and histological inflammation is associated with poorer outcomes in ulcerative colitis (UC). Fecal calprotectin is a surrogate marker of endoscopic and histological remission. AIMS: To confirm the correlation between fecal calprotectin and endoscopic or histological disease activity and to define the optimal cutoff value to detect endoscopic and histological remission. METHODS: From a prospectively maintained database, we analyzed 61 UC patients who had fecal calprotectin measurement and endoscopy performed within 1 month. Endoscopic activity was graded using the Mayo endoscopic subscore (MES). Histological remission was defined as normal histology or quiescent histological activity. RESULTS: Eighteen patients (29.5%) and five patients (8.1%) had endoscopic remission defined as MES ≤ 1 or MES = 0, respectively. We observed a significantly lower median level of fecal calprotectin in patients with endoscopic remission than those with endoscopic activity for both definition of endoscopic remission, i.e., MES ≤ 1 (158 vs 490 µg/g, p = 0.0005) or MES = 0 (94 vs 414 µg/g, p = 0.013). Seven patients (11.5%) were in histological remission. They had a lower median level of fecal calprotectin than those with active histological inflammation (107 vs 416 µg/g, p = 0.016). Using a ROC curve, fecal calprotectin < 250 µg/g predicted endoscopic remission (MES ≤ 1) with a sensitivity of 67% and specificity of 77%, while fecal calprotectin < 200 µg/g predicted histological remission with a sensitivity of 71% and specificity of 76%. CONCLUSION: Fecal calprotectin level correlated with both endoscopic activity and histological activity and is a reliable biomarker in assessing mucosal healing in UC.
BACKGROUND: Persistent active endoscopic and histological inflammation is associated with poorer outcomes in ulcerative colitis (UC). Fecal calprotectin is a surrogate marker of endoscopic and histological remission. AIMS: To confirm the correlation between fecal calprotectin and endoscopic or histological disease activity and to define the optimal cutoff value to detect endoscopic and histological remission. METHODS: From a prospectively maintained database, we analyzed 61 UC patients who had fecal calprotectin measurement and endoscopy performed within 1 month. Endoscopic activity was graded using the Mayo endoscopic subscore (MES). Histological remission was defined as normal histology or quiescent histological activity. RESULTS: Eighteen patients (29.5%) and five patients (8.1%) had endoscopic remission defined as MES ≤ 1 or MES = 0, respectively. We observed a significantly lower median level of fecal calprotectin in patients with endoscopic remission than those with endoscopic activity for both definition of endoscopic remission, i.e., MES ≤ 1 (158 vs 490 µg/g, p = 0.0005) or MES = 0 (94 vs 414 µg/g, p = 0.013). Seven patients (11.5%) were in histological remission. They had a lower median level of fecal calprotectin than those with active histological inflammation (107 vs 416 µg/g, p = 0.016). Using a ROC curve, fecal calprotectin < 250 µg/g predicted endoscopic remission (MES ≤ 1) with a sensitivity of 67% and specificity of 77%, while fecal calprotectin < 200 µg/g predicted histological remission with a sensitivity of 71% and specificity of 76%. CONCLUSION: Fecal calprotectin level correlated with both endoscopic activity and histological activity and is a reliable biomarker in assessing mucosal healing in UC.
Authors: Fernando Magro; Andreia Rodrigues; Ana Isabel Vieira; Francisco Portela; Isabelle Cremers; José Cotter; Luis Correia; Maria Antónia Duarte; Maria Lourdes Tavares; Paula Lago; Paula Ministro; Paula Peixe; Susana Lopes; Elizabeth Benito Garcia Journal: Inflamm Bowel Dis Date: 2011-07-26 Impact factor: 5.325
Authors: Talat Bessissow; Bart Lemmens; Marc Ferrante; Raf Bisschops; Kristel Van Steen; Karel Geboes; Gert Van Assche; Séverine Vermeire; Paul Rutgeerts; Gert De Hertogh Journal: Am J Gastroenterol Date: 2012-11-13 Impact factor: 10.864
Authors: Britt Christensen; Stephen B Hanauer; Jonathan Erlich; Olufemi Kassim; Peter R Gibson; Jerrold R Turner; John Hart; David T Rubin Journal: Clin Gastroenterol Hepatol Date: 2017-02-24 Impact factor: 11.382
Authors: Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Ekaterina Safroneeva; Yvonne Romero; David Armstrong; Carsten Schmidt; Michael Trummler; Valérie Pittet; Stephan R Vavricka Journal: Inflamm Bowel Dis Date: 2013-02 Impact factor: 5.325
Authors: David T Rubin; Dezheng Huo; Jami A Kinnucan; Mina S Sedrak; Nicole E McCullom; Alana P Bunnag; Elin P Raun-Royer; Russell D Cohen; Stephen B Hanauer; John Hart; Jerrold R Turner Journal: Clin Gastroenterol Hepatol Date: 2013-07-17 Impact factor: 11.382
Authors: Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682
Authors: L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel Journal: Am J Gastroenterol Date: 2015-08-25 Impact factor: 10.864
Authors: Joshua B Wechsler; Steven J Ackerman; Mirna Chehade; Katie Amsden; Mary E Riffle; Ming-Yu Wang; Jian Du; Matt L Kleinjan; Preeth Alumkal; Elizabeth Gray; Kwang-Youn A Kim; Barry K Wershil; Amir F Kagalwalla Journal: Allergy Date: 2021-05-10 Impact factor: 14.710
Authors: Allison Ross Eckard; Heather Y Hughes; Nancy L Hagood; Mary Ann O'Riordan; Danielle Labbato; Julia C Kosco; Sarah E Scott; Grace A McComsey Journal: J Acquir Immune Defic Syndr Date: 2021-02-01 Impact factor: 3.771
Authors: Parambir S Dulai; Robert Battat; Maria Barsky; Nghia H Nguyen; Christopher Ma; Neeraj Narula; Mahmoud Mosli; Niels Vande Casteele; Brigid S Boland; Larry Prokop; M Hassan Murad; Geert D'Haens; Brian G Feagan; William J Sandborn; Vipul Jairath; Siddharth Singh Journal: Am J Gastroenterol Date: 2020-06 Impact factor: 12.045